

**98-0206**

The invention relates to the medicine and is provided for treatment of patients having rheumatoid diseases.

The proposed preparation comprises the thermally modified human G immunoglobulin in the form of a 10% aqueous solution and a corpuscular carrier in the form of a 10-16% aqueous suspension of sterile conserved human erythrocytes in the volume ratio of components respectively within the limits of 1:6...1:10.

The technical result consists in the inhibition of the rheumatoid factor synthesis, in the immunostimulating and anti-inflammatory action and in the creation of a deposition effect.

Claims: 3